A minimum specification dataset for liquid ocular endotamponades: recommendations by a European expert panel

被引：0
|
作者：
Mariantonia Ferrara
David HW Steel
Mario R Romano
机构：
[1] Manchester Royal Eye Hospital,Department of Biomedical Sciences
[2] Sunderland Eye Infirmary,Department of Ophthalmology
[3] Bioscience Institute,undefined
[4] Newcastle University,undefined
[5] Humanitas University,undefined
[6] Humanitas Gavazzeni-Castelli,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2024年 / 262卷
关键词：
Biocompatibility; Ocular endotamponades; Perfluorocarbon liquids; Purity; Safety assessment; Silicone oil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1141 / 1149
页数：8
相关论文
共 24 条
  • [21] BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
    Soverini, Simona
    Hochhaus, Andreas
    Nicolini, Franck E.
    Gruber, Franz
    Lange, Thoralf
    Saglio, Giuseppe
    Pane, Fabrizio
    Mueller, Martin C.
    Ernst, Thomas
    Rosti, Gianantonio
    Porkka, Kimmo
    Baccarani, Michele
    Cross, Nicholas C. P.
    Martinelli, Giovanni
    BLOOD, 2011, 118 (05) : 1208 - 1215
  • [22] Recommendations on the use of alloHSCT for patients with MDS and chronic myelomonocytic leukemia: prepared by 22 members from an expert panel from EBMT Chronic Malignancies Working Party, European LeukemiaNet and MDS Foundation
    De Witte, T.
    Mufti, G.
    Bowen, D.
    Malcovati, L.
    Niederwieser, D.
    Yakoub-Agha, I.
    Robin, M.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S110 - S110
  • [23] Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96)
    Onal, Sumru
    Tugal-Tutkun, Ilknur
    OPHTHALMOLOGY, 2014, 121 (10) : E57 - E58
  • [24] Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96) Reply
    Read, Russell W.
    Levy-Clarke, Grace
    Jabs, Douglas A.
    Rosenbaum, James T.
    Vitale, Albert
    Van Gelder, Russell N.
    OPHTHALMOLOGY, 2014, 121 (10) : E58 - E59
123